Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

29050 reported adverse events

Drugs of this class: NIRAPARIB OLAPARIB

These side effects are most commonly reported by patients taking drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class:

# Side effect Count
0 NAUSEA 5947
1 FATIGUE 5302
2 DEATH 4001
3 CONSTIPATION 3753
4 PLATELET COUNT DECREASED 3628
5 OFF LABEL USE 2585
6 MALIGNANT NEOPLASM PROGRESSION 2554
7 INSOMNIA 2511
8 ANAEMIA 2176
9 BLOOD PRESSURE INCREASED 2167
See all common reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

Drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARBOHYDRATE ANTIGEN 125 INCREASED 1918 0.6332
1 CARBOHYDRATE ANTIGEN 125 10 0.5000
2 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS 37 0.5000
3 OVARIAN CANCER RECURRENT 468 0.4597
4 ACUTE ERYTHROID LEUKAEMIA 14 0.4516
5 BRCA2 GENE MUTATION 19 0.2639
6 RECURRENT CANCER 690 0.2256
7 SCAN ABNORMAL 51 0.1932
8 BRCA1 GENE MUTATION 10 0.1887
9 DRUG MONITORING PROCEDURE NOT PERFORMED 241 0.1783
See all enriched reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]